-
Je něco špatně v tomto záznamu ?
Non-antibiotic antibacterial peptides and proteins of Escherichia coli: efficacy and potency of bacteriocins
J. Bosák, M. Hrala, L. Micenková, D. Šmajs
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- antibakteriální látky biosyntéza izolace a purifikace farmakologie MeSH
- bakteriociny biosyntéza izolace a purifikace farmakologie MeSH
- Escherichia coli metabolismus MeSH
- koliciny biosyntéza izolace a purifikace farmakologie MeSH
- lidé MeSH
- probiotika farmakologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
INTRODUCTION: The emergence and spread of antibiotic resistance among pathogenic bacteria drives the search for alternative antimicrobial therapies. Bacteriocins represent a potential alternative to antibiotic treatment. In contrast to antibiotics, bacteriocins are peptides or proteins that have relatively narrow spectra of antibacterial activities and are produced by a wide range of bacterial species. Bacteriocins of Escherichia coli are historically classified as microcins and colicins, and, until now, more than 30 different bacteriocin types have been identified and characterized. AREAS COVERED: We performed bibliographical searches of online databases to review the literature regarding bacteriocins produced by E. coli with respect to their occurrence, bacteriocin role in bacterial colonization and pathogenicity, and application of their antimicrobial effect. EXPERT OPINION: The potential use of bacteriocins for applications in human and animal medicine and the food industry includes (i) the use of bacteriocin-producing probiotic strains, (ii) recombinant production in plants and application in food, and (iii) application of purified bacteriocins.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026008
- 003
- CZ-PrNML
- 005
- 20211026133304.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14787210.2020.1816824 $2 doi
- 035 __
- $a (PubMed)32856960
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Bosák, Juraj $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 245 10
- $a Non-antibiotic antibacterial peptides and proteins of Escherichia coli: efficacy and potency of bacteriocins / $c J. Bosák, M. Hrala, L. Micenková, D. Šmajs
- 520 9_
- $a INTRODUCTION: The emergence and spread of antibiotic resistance among pathogenic bacteria drives the search for alternative antimicrobial therapies. Bacteriocins represent a potential alternative to antibiotic treatment. In contrast to antibiotics, bacteriocins are peptides or proteins that have relatively narrow spectra of antibacterial activities and are produced by a wide range of bacterial species. Bacteriocins of Escherichia coli are historically classified as microcins and colicins, and, until now, more than 30 different bacteriocin types have been identified and characterized. AREAS COVERED: We performed bibliographical searches of online databases to review the literature regarding bacteriocins produced by E. coli with respect to their occurrence, bacteriocin role in bacterial colonization and pathogenicity, and application of their antimicrobial effect. EXPERT OPINION: The potential use of bacteriocins for applications in human and animal medicine and the food industry includes (i) the use of bacteriocin-producing probiotic strains, (ii) recombinant production in plants and application in food, and (iii) application of purified bacteriocins.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antibakteriální látky $x biosyntéza $x izolace a purifikace $x farmakologie $7 D000900
- 650 _2
- $a bakteriociny $x biosyntéza $x izolace a purifikace $x farmakologie $7 D001430
- 650 _2
- $a koliciny $x biosyntéza $x izolace a purifikace $x farmakologie $7 D003087
- 650 _2
- $a Escherichia coli $x metabolismus $7 D004926
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a probiotika $x farmakologie $7 D019936
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hrala, Matěj $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Micenková, Lenka $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Šmajs, David $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00174403 $t Expert review of anti-infective therapy $x 1744-8336 $g Roč. 19, č. 3 (2021), s. 309-322
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32856960 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133310 $b ABA008
- 999 __
- $a ok $b bmc $g 1714885 $s 1146515
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 19 $c 3 $d 309-322 $e 20200922 $i 1744-8336 $m Expert review of anti-infective therapy $n Expert Rev Anti Infect Ther $x MED00174403
- LZP __
- $a Pubmed-20211013
